Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options: results from a phase I study
Lenalidomide is an immunomodulatory drug approved for multiple myeloma, relapsed mantle cell lymphoma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogenetic responses seen in del(5q) MDS, several trials have been
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 2019
|
| In: |
Haematologica
Year: 2019, Volume: 104, Issue: 2, Pages: e63-e64 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2018.199794 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2018.199794 Verlag, Volltext: http://www.haematologica.org/content/104/2/e63 
|
| Author Notes: | Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, Richard F. Schlenk |
| Summary: | Lenalidomide is an immunomodulatory drug approved for multiple myeloma, relapsed mantle cell lymphoma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogenetic responses seen in del(5q) MDS, several trials have been |
|---|---|
| Item Description: | Gesehen am 28.02.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2018.199794 |